The Lancet. OncologyAged80 and overHumansMaleMiddle Aged
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial.
Louise Kostos, James P Buteau, Jing Xie, Anthony Cardin, Tim Akhurst, Ramin Alipour, Lewis Au, Joanna Chan, Kwang Y Chin, Brittany Emmerson, Luc Furic, Quinn Garcia, Anthony J Hamilton, Mohammad B Haskali, Price A Jackson
Published: 202510.1016/S1470-2045(25)00559-5
Abstract
BACKGROUND: Lutetium-177 [177Lu]Lu-PSMA-I&T (177Lu-PSMA-I&T) and the bone-seeking α-emitter radium-223 (223Ra) are established life-extending therapies for patients with metastatic castration-resistant prostate cancer; however, resistance and progres…
Preview only. Read the full abstract at the source